Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

about

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

Item

http://www.wikidata.org/entity/Q52606456

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@en

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@nl

type

Item

label

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@en

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@nl

prefLabel

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@en

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@nl

P1476

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

@en

P2093

Bryan M Burt

http://www.w3.org/2001/XMLSchema#string

Farrah Kheradmand

http://www.w3.org/2001/XMLSchema#string

Hee-Jin Jang

http://www.w3.org/2001/XMLSchema#string

Hyun-Sung Lee

http://www.w3.org/2001/XMLSchema#string

Jong Min Choi

http://www.w3.org/2001/XMLSchema#string

Ju-Seog Lee

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Peter T Jindra

http://www.w3.org/2001/XMLSchema#string

Ronald H Kerman

http://www.w3.org/2001/XMLSchema#string

Sung Yun Jung

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Algorithmic Tools for Mining High-Dimensional Cytometry Data

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Genetic basis for clinical response to CTLA-4 blockade in melanoma

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

P31

scholarly article

P356

10.1172/JCI.INSIGHT.98575

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David J. Sugarbaker

P577

2018-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29618661

http://www.w3.org/2001/XMLSchema#string

P932

5928857

http://www.w3.org/2001/XMLSchema#string